fbpx

Type to search

Takeda CEO Sees Workforce Shifting: Nikkei Asia

CEO Christophe Weber has streamlined operations by selling off consumer pharmaceutical and diabetic treatment businesses


Takeda
Takeda Pharmaceuticals' logo is seen outside its headquarters in Tokyo. Photo: Reuters

 

More than half of the employees at Japanese pharmaceuticals giant Takeda would work in emerging markets a decade from now as the company accelerates its globalisation, Nikkei Asia reported.

According to Takeda, 18% of its 47,000 employees are currently based in emerging markets, compared with 39% in the US and 32% in Europe and Canada. Japan hosts 11% of the workforce.

Christophe Weber, the chief executive, has streamlined Takeda’s operations by selling off consumer pharmaceutical and diabetic treatment businesses. The company now focuses on cancer, digestive and nervous system disorders, as well as rare diseases.

Read the full report: Nikkei Asia

 

READ MORE:

China Power Crisis May Hit Indian Pharma Sector: BS

India’s Gland Pharma to Make Russian Sputnik V Covid Vaccine

 

 

George Russell

George Russell is a freelance writer and editor based in Hong Kong who has lived in Asia since 1996. His work has been published in the Financial Times, The Wall Street Journal, Bloomberg, New York Post, Variety, Forbes and the South China Morning Post.

logo

AF China Bond